Genome Medicine | Volume 1 Issue 12

Advanced search

Submit a manuscript Register Follow us on

Explore journal

Articles

cover

	Volume 1 Issue 12
	Comment
	Commentary Human genomics and preparedness for infectious threats Nicole F Dowling, Marta Gwinn, Alison Mawle Genome Medicine 2009, 1:119 (29 December 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Research activity during infectious disease outbreaks maximizes limited resources, enhances gains in scientific knowledge, and ultimately increases levels of preparedness.
	Musings Musings on genome medicine: enzyme-replacement therapy of the lysosomal storage diseases David G Nathan, Stuart H Orkin Genome Medicine 2009, 1:114 (9 December 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Enzyme replacement therapies are costly and incomplete but may save lives until more effective therapy is developed, however preventive strategies such as carrier detection should be considered for future management of rare lysosomal storage diseases.
	Review
	Minireview Measuring cis-acting regulatory variants genome-wide: new insights into expression genetics and disease susceptibility Wolfgang Sadee Genome Medicine 2009, 1:116 (22 December 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary A recent large-scale allelic expression analysis shows that cis-acting regulatory variants might reveal some of the 'missing heritability' component of complex disorders, which could lead to potential therapy and prevention breakthroughs.
	Review Metabolic adaptation of skeletal muscle to high altitude hypoxia: how new technologies could resolve the controversies Andrew J Murray Genome Medicine 2009, 1:117 (18 December 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary An integrated and quantitative understanding of the body’s metabolic response to high altitude and the conditions under which adaptive processes occur could reveal much about the ways that tissues function in disease states where hypoxia is a critical factor.
	Review What lies behind serum urate concentration? Insights from genetic and genomic studies Kimiyoshi Ichida Genome Medicine 2009, 1:118 (29 December 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Recent genome-wide studies have identified novel candidate genes related to urate metabolism and transport, but their physiological roles and the influence of environmental factors remain unclear.
	Review Pharmacogenomic insights into treatment and management of statin-induced myopathy Bas JM Peters, Olaf H Klungel, Frank L Visseren, Anthonius de Boer, Anke-Hilse Maitland-van der Zee Genome Medicine 2009, 1:120 (29 December 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Genotyping in patients suffering from statin-induced myopathy may help to personalize the choice of statin by reducing the chance of developing this rare but serious side-effect.
	Research
	Research Increased hepatic oxidative metabolism distinguishes the action of Peroxisome proliferator-activated receptor δ from Peroxisome proliferator-activated receptor γ in the ob/ob mouse Lee D Roberts, David G Hassall, Deborah A Winegar, John N Haselden, Andrew W Nicholls, Julian L Griffin Genome Medicine 2009, 1:115 (7 December 2009) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Peroxisome proliferator-activated receptor (PPAR) delta plays a distinct catabolic role by activating hepatic and peripheral fatty acid oxidative metabolism, highlighting its potential as a therapeutic target for dyslipidaemia and metabolic syndrome.
	Research Postmenopausal estrogen and progestin effects on the serum proteome Sharon J Pitteri, Samir M Hanash, Aaron Aragaki, Lynn M Amon, Lin Chen, Tina Busald Buson, Sophie Paczesny, Hiroyuki Katayama, Hong Wang, Melissa M Johnson, Qing Zhang, Martin McIntosh, Pei Wang, Charles Kooperberg, Jacques E Rossouw, Rebecca D Jackson, JoAnn E Manson, Judith Hsia, Simin Liu, Lisa Martin, Ross L Prentice Genome Medicine 2009, 1:121 (24 December 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Estrogen plus progestin and estrogen-alone have different effects on proteins involved in growth factor and inflammation pathways, providing an explanation for the distinctive clinical effects of each therapy.